Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Mostrar más
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | -6.925 | -13.326277302 | 51.965 | 53.99 | 44.37 | 446084 | 47.01409958 | CS |
| 4 | -6.49 | -12.5946050844 | 51.53 | 63.5 | 44.37 | 388689 | 53.69749592 | CS |
| 12 | -3.23 | -6.69152682826 | 48.27 | 63.5 | 44.37 | 415220 | 53.85524732 | CS |
| 26 | -6.9 | -13.2845591067 | 51.94 | 63.5 | 36.26 | 423374 | 48.16190565 | CS |
| 52 | 27.31 | 154.032712916 | 17.73 | 72.29 | 16.39 | 473058 | 48.79792935 | CS |
| 156 | 23.54 | 109.488372093 | 21.5 | 72.29 | 14.19 | 435775 | 43.01225553 | CS |
| 260 | 23.54 | 109.488372093 | 21.5 | 72.29 | 14.19 | 435775 | 43.01225553 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
